Thomas Edlund new Chairman of Pharmalink

The Swedish specialty pharmaceutical company Pharmalink announced the appointment of Thomas Eklund as Chairman of the board.

Thomas Eklund joined the board on August 15, 2017.

Bengt Julander, Founder and outgoing Chairman of Pharmalink, said: "We are very happy to have Thomas on board as we prepare for taking our lead candidate drug Nefecon through a clinical Phase 3 study for patients with primary IgA nephropathy.

"Thomas’s broad knowledge and long experience from both the healthcare industry and the financial sector will be a welcome addition to the team."

Thomas has extensive experience from the pharmaceutical industry, medtech industry and the financial sector where he has held different leading positions, including CEO and Head of Europe at Investor Growth Capital.

Other previous positions include Investment Director at Alfred Berg ABN AMRO Capital Investment and VP at Handelsbanken Markets. He is currently Chairman of the board of Moberg Pharma and Itrim, and board member of Boule Diagnostics, Biotage, Neoventa Medical, Memira and Rodebjer Form.

You may also like

Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Ingredients

Full details from Calliditas Therapeutics’ Phase 3 study released

Calliditas Therapeutics has announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon delayed release capsules in adults with Primary IgA nephropathy
Regulatory

Calliditas receives fast track FDA designation for PBC candidate

The FDA program facilitates the expedited development and review of new drugs intended to treat serious or life-threatening conditions
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Subscribe now